Pulse.

a daily field guide to health research that matters

◆ Console

‹ Fri · 6 Nov 2026
Promising but preliminary

Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial.

A novel combination therapy shows early promise and acceptable tolerability in advanced triple-negative breast cancer, requiring larger testing.

A single-arm phase 1b/2 study evaluated pumitamig plus nab-paclitaxel in advanced or metastatic triple-negative breast cancer. Early activity was encouraging and no treatment-related deaths occurred, but randomized confirmation is required.

What the study was

Study design
Single-arm phase 1b/2 clinical trial
Population
Patients receiving first-line therapy for advanced or metastatic triple-negative breast cancer
Category
Treatment Innovation
Maturity
Exploratory
Journal
The Lancet. Oncology

Why it surfaced

The trial reports clinically relevant early efficacy in an aggressive cancer, with single-arm and early-phase limitations.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.